Translating Indoor Air Quality Data Into Action

November 6, 2026 updated by: Boston University

Translating Indoor Air Quality Data Into Action: A Randomized Trial Of Tiered Information Strategies To Improve Household Air Quality

Poor indoor air quality affects the health of millions of Americans. People spend most of their time indoors, yet indoor air can be more polluted than outdoor air. Many everyday activities, such as cooking, using fireplaces, cleaning, and using air fresheners, affect indoor air quality, but most people don't know how their choices affect the air they breathe.

This study will test whether giving people information about their indoor air quality motivates them to make healthier choices. We will work with 120 households, providing them with air quality monitors and sending different types of information about their indoor air quality. Through randomized assignment, some will receive general tips, while others will get personalized messages based on their home's air quality patterns.

By understanding how to best help people create healthier indoor environments, respiratory health can e protected across diverse communities. This research could lead to practical, affordable ways for families to breathe cleaner air at home.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
120

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Kipruto Kirwa, PhD, MPH
  • Phone Number: 617-358-1911
  • Email: kirwa@bu.edu

Study Contact Backup

  • Name: Eliza Pentz, MS
  • Phone Number: 617-358-3728
  • Email: eppentz@bu.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

21 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Is an active female participant in PRESTO (aged 21-45 years and trying to conceive at PRESTO enrollment, per PRESTO eligibility) who has completed the PRESTO baseline questionnaire and has not withdrawn from PRESTO.
  2. Lives in the United States and has a residence where a monitor can be safely placed for approximately four months after the baseline period.
  3. Has home Wi-Fi internet that the monitor can connect to.
  4. Has a smartphone or tablet that can run the monitor's companion app.
  5. Does not plan to move out of her current home within the next 6 months.
  6. Is willing to complete the study activities: monthly online questionnaires for 6 months, four 2-day activity logs, keeping the monitor plugged in at home for about 4 months, undergo random assignment, receiving study emails, text messages, and other communication, and returning the monitor at the end.
  7. Be able to provide informed consent in English.

Exclusion Criteria:

  1. Currently has an indoor air quality monitor in the home that displays levels of particles, VOCs, or CO2 (smoke alarms, carbon monoxide alarms, and radon detectors do not count). Rationale: households that already see IAQ data cannot provide a true "no-monitor" baseline period.
  2. Is an employee, student, or trainee of any member of the study team.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: LCM-O (monitor only)

Participants randomized to this arm will only receive a LCM-O monitor.
Other: LCM-O (monitor only)

Indoor air quality monitor with real-time display and companion app; standard setup and safety guide; routine study operational messages (e.g., questionnaire reminders), which contain no IAQ content.
Active Comparator: LCM-R (monitor + generic reminders)

Participants randomized to this arm will receive a LCM-O monitor and generic reminders.
Other: LCM-R (monitor + generic reminders)

Everything in Arm 1, plus a brief generic IAQ tip and reminder to review the monitor every two weeks, drawn from a fixed library based on EPA guidance and the literature (8 messages over 4 months, starting 2 weeks after activation).
Experimental: LCM-I (monitor + personalized insights)

Participants randomized to this arm will receive a LCM-O monitor and personalized insights.
Other: LCM-I (monitor + personalized insights)

Everything in Arm 1, plus a personalized message every two weeks that describes patterns in the household's own monitor data from the previous 14 days and suggests one or two specific actions, with links to further information (8 messages, starting 2 weeks after activation).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Indoor Air Quality (IAQ) Behavior Score
Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months

The IAQ Behavior Score measures how human actions, habits, or responses contribute to or mitigate indoor pollution. Data will be collected from a IAQ questionnaire. The score will range from 1-100 and higher scores are more favorable.
Baseline, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Boston University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
American Lung Association

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Kipruto Kirrwa, PhD, MPH, Boston University School of Public Health, Environmental Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 1, 2027

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2029

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 1, 2029

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 6, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 6, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 12, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 6, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • H-47323
  • IAA-1579103 (Other Grant/Funding Number: American Lung Association)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings